Who are BMN 110 - Every Other Week's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Naglazyme®, ALGLUCOSIDASE ALFA (MYOZYME), Pancrelipase Capsules, alpha-1-Proteinase Inhibitor, Cerezyme®, Myozyme® (alglucosidase alfa).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bmn-110-every-other-week.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

BMN 110 - Every Other Week — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BMN 110 - Every Other Week (BMN 110 - Every Other Week) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Rare genetic metabolic disorder.

phase 3 Enzyme replacement therapy Lysosomal acid lipase (LAL) Rare genetic metabolic disorder Small molecule Live · refreshed every 30 min

Target snapshot

BMN 110 - Every Other Week (BMN 110 - Every Other Week) — BioMarin Pharmaceutical. BMN 110 is a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy that restores deficient enzyme activity in patients with LAL deficiency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BMN 110 - Every Other Week TARGET	BMN 110 - Every Other Week	BioMarin Pharmaceutical	phase 3	Enzyme replacement therapy	Lysosomal acid lipase (LAL)
Naglazyme®	Naglazyme®	Masonic Cancer Center, University of Minnesota	marketed	Enzyme replacement therapy	Arylsulfatase B (ARSB)
ALGLUCOSIDASE ALFA (MYOZYME)	ALGLUCOSIDASE ALFA (MYOZYME)	Genzyme, a Sanofi Company	marketed	Enzyme replacement therapy	Acid alpha-glucosidase (GAA)
Pancrelipase Capsules	Pancrelipase Capsules	Ohio State University	marketed	Pancreatic enzyme replacement therapy
alpha-1-Proteinase Inhibitor	alpha-1-Proteinase Inhibitor	Institute for Human Genetics and Biochemistry	marketed	Protease inhibitor / Enzyme replacement therapy	Neutrophil elastase
Cerezyme®	Cerezyme®	ISU Abxis Co., Ltd.	marketed	Enzyme replacement therapy	Glucocerebrosidase (β-glucosidase)
Myozyme® (alglucosidase alfa)	Myozyme® (alglucosidase alfa)	Genzyme, a Sanofi Company	marketed	Enzyme replacement therapy	Acid alpha-glucosidase (GAA); lysosomal glycogen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BMN 110 - Every Other Week — Competitive Intelligence Brief. https://druglandscape.com/ci/bmn-110-every-other-week. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab